ArticleCancers2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.
Maria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, Urban Novak, Nicolas Mach, Thorsten Zenz, Lisa Holer, Luciano Cascione, Eleonora Cannas, Andrea Rinaldi and 5 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Maria Cristina PirosaInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Dagmar HessKantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
Urban NovakDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-7642-2101 Thorsten ZenzUniversitätsspital Zürich, 8091 Zürich, Switzerland.
Lisa HolerCompetence Center of SAKK, 3008 Bern, Switzerland.
Luciano CascioneInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-4606-0637 Eleonora CannasInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0009-0000-9551-7122 Andrea RinaldiInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Sämi SchärCompetence Center of SAKK, 3008 Bern, Switzerland.
Emanuele ZuccaInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-5522-6109 Francesco BertoniInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0001-5637-8983 Anastasios StathisOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Swiss Group for Clinical Cancer Research SAKK
Funding
Swiss Group For Clinical Cancer Research KFS-4727-02-2019
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
B-cell lymphomaBCL2 inhibitorearly-phase trialPI3K inhibitor
Identifiers
PMID42279347
PMCPMC13255691
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390